Johnson & Johnson (JNJ)[Tv]
Monthly Analysis
Sector: Healthcare
Key Developments
-
FDA accepts protocol amendment to accelerate pivotal NANORAY-312 trial for NBTXR3 (JNJ-1900) in inoperable NSCLC, following positive Phase 2 CONVERGE data showing an 85.7% overall response rate and 57.1% complete response rate—a major therapeutic and regulatory inflection point with blockbuster potential.
-
FDA grants Priority Review for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, based on transformative Phase 2/3 ENERGY trial results showing a threefold increase in durable hemoglobin response, rapid onset, and reduced steroid dependence—a near-term catalyst with major market re-rating implications.
-
$1 billion all-cash acquisition of Firefly Bio, Inc. announced, set to close in 2026—the most consequential strategic move of the year, securing a leading degrader-antibody conjugate platform targeting KRAS-driven solid tumors and reinforcing JNJ’s bold bet on next-generation oncology innovation.
This content is for informational purposes only and does not constitute financial, investment, or trading advice. Always consult a qualified financial professional before making any investment decisions.